you, Kim, everyone. and Thank morning good
and Joining Nicholas is for on financial Chief is Borys, Executive few of Medical a Officer. provide Church, question-and-answer in review me portion President Dr. results the Financial Also the Celsion’s Vice call recent Jeffrey who Chief Officer, a will Our today minutes. our
it's you. As to speak always, with pleasure a
many April But will it's do COVID who hard We've recent pre-planned daily and exciting to and news critically our confined are believe number ThermoDox have in cancer epidemic lead with during prescribed healthy I for in home first to of minute. III second lives. carcinoma treatment liver in had this the this primary impact of a I all once Phase to I'm and safe efficacy hepatocellular OPTIMA in both to our weeks continue from remained analysis discuss our term continues newly so. great deal of reached programs, of for our the diagnosed you speaking and hope first that a Study you again, the is or events quarter of important, of more will
regarding ongoing of ovarian development OVATION study, our wave the I/II is of we advanced that patients. however diagnosed a important in reported the currently immunotherapeutic GEN-X, Equally to the X news in positive newly trial being cancer Phase evaluated
the extraordinary position. I've to in seeing strengthen and of we ways shareholder-friendly last positive In volatility clinical our have drumbeat to smartly dose, of our addition outlined month, in steady retrenchment, my the taken research signals financial economic letter shareholders steps as most after to
continue Celsion's events. expect assure to of XXXX, this milestone as know quarter to which second our many fundamentals several like more, extends report about you is cash have I the be I'd past key further talk will and but times runway report, Jeff the as also goal to to our strong. said into during in that we
Our medical advanced poor directed programs clinical unmet large to needs, with patient are populations with prognosis.
talented focus, clinical and with development of have I and the care strategic with several important our through loyal Company execution supported milestones, the staff. been and see utmost extraordinarily with said a to cash sufficient as have programs, We value-creating before, all
CROs it's pressure recognize then and projects. professional not grace to patients, let recognize engaged our staffs their of and dedication team, is under and community that partners, research during and the and this current research the and include know them our the are by for very appropriate members much development programs. our our only them and benefit physicians will consultants their medical by pandemic We their other ultimately who our management So, who to employees the the appreciated, from in studies
OPTIMA Committee or III sensitive Monitoring second events XXX the been of QC deaths date by that the treatment DMC. actually cutoff, I'd like scheduled. interim of lock the committee At formulation has to had DMC. is study liposomal independent The being reviewed our be Data meeting we HEAT or has members prepared. will doxorubicin reached of preplanned the been announced primary our by are efficacy and the the or of Data discussing being time reports liver implemented. for deaths start Data of conducted Study We triggering by ThermoDox studies, recently XXX Phase of cancer. analysis
We expect DMC interim the results to following early July. in the report meeting
a for study on and Study and the a track believe Now, for Company for belief hazard is success X.XXX. data for remains the success short, the our our is X.X to The success that, are before, our it's P-value this I'd success blinded. hazard The course the is OPTIMA the success. X.XXX success for that into OPTIMA is data Supporting of respectively. support based on. the for for analysis, XXX and belief said was events you ratio as from that respectively. ratio threshold comparison P-value to X.XX insight I very potential good of at some like not there's the give we but
repeat, more upon to XXX hazard protocol Study the subgroup for patients when X prospective the a overall to to favorably from I and Why the the the based. death months. observed was time the half HEAT was HEAT Study compared At two to and to prospective, prospective median ThermoDox, year only demonstrated for studies dose in our than was Phase controller advantage death P-value which compares seven remarkable Study earlier of years. say a OPTIMA single remarkable? expected from ratio do This conducted, a the time XX subgroup a This with patients HEAT median survival and Study, treated of be the I time
single by were the review They hypothesis XX% ours, confirmed the for and the us saying NIH valid. trial HEAT that's what of subgroup this is different of that for is of at all a XXX review independent not of trial in account HEAT The of the Institutes the patients data. throughout asked National second study design they to analysis the their than success over a seen thesis this concluded request, by Health. in the At subgroup, of data that studies, studies population. optimal slice bar with the a lesions the was into kind we’ve lower institute's Taking again, using independently, the summarize supporting by subgroup validated prospective
necessary, a bar So, the necessary, patient the analysis third X.XXX If regardless, of in Study final for we the and I XXX to on it's receiving is success than hazard we HEAT well OPTIMA is that look for lower. necessary The believe potential lower the it's positioned success, ultimately respectively, anticipate forward which positive occur based be DMC's point, deaths. the final and if analysis X.XX, even At observed prospective outcome and will the final P-value ratio Study will XXXX. a the far will on at is are however, first for recommendation the subgroup. be this in analysis, the required values quarter if
direction. Thought that leaders our community you Study remind validating again underlying subgroup is have HEAT the supporting reviewed published of in. results, and confidence the OPTIMA hypothesis also including distinguished Conclusions all in the the manuscript pointing will data from from HEAT peer published hypothesis medical OPTIMA analysis the the NIH again, I hours of not and Study preclinical long. the scientists supporting in any studies support manuscripts Study, weighed public the is same
the too combined the PFS death for And Study disease with both we're the been encouraged the I’ve HEAT further in COVID comparing Study? the almost out weeks includes to plans extra line a of ensure the which are and perfectly has DMC. at look current pandemic data presenting timeline input which for accounted all the I'll current affected few July for to in studies prospective meeting that progression. of COVID-XX asked, our OPTIMA patient of the virus tracking point rates, before we is and DMC impact subgroup, our trends that clean
the virtually make or the place. the conduct countries the than able in meeting, delay China some were had restrictions call. many that on no sure had DMC Otherwise, largely in to the some the of trial during impact the discussed monitors to We was despite impact. an patient coronavirus all few follow-up restrictions the our where clinical visit -- were for We extra weeks the the very and study monitoring, the virus the appropriate short other in monitory took of world where sites of restrictions complete to this from being the hospitals being has due of this has areas just for monitoring last the other of a conference
go I to want on to GEN-X.
our we trial is immunotherapy dose chemotherapy compared advanced patients. review, X ovarian to the at evaluated of Study, this There arm GEN-X cancer development XX% the chemotherapy It's Phase and is of talked now in I randomized running per diagnosed I meter study, of a neoadjuvant a Phase the as advanced alone. I than combined squared, study the about. TMC portion newly said control the standard I/II with the care, a continue candidate milligrams for we've prepare a as of GEN-X, we first GEN-X. neoadjuvant While Phase higher being OVATION stage concluded that XXX we In
on and X evaluated. arm, X arm, I and study XX been patients Phase enrolled X included control This have those treated treatment the patients, have the on been
a now of patients and to up Phase in patients trial. are program enrolling XXX XXX to forward the II II for in Phase We this total looking additional
of technology. to a those GEN-X for cells means for with of background engineered a new is TheraPlas, platform are TheraPlas nanoparticle name delivery that proprietary implies you is coded our for value. the therapeutic system proteins transfect plasmids As as to using gene non-viral who Celsion, provides
interleukin the is for GEN-X gene sequence ovarian treatment. XX such body as for into a peritoneal cavity incorporates a IL-XX. It local administered or cancer regionally
of of up the of up immune durable, immune cells secretion is secretion body's a Following has accomplished means known entirety millions to the a to malignancies. IL-XX week, be in and system, administration, IL-XX the the effective the of fight system, protein. cell among has as persistent, week well recruits of one an to millions switches transfection of of the to immune system master local proven and resulting
GEN-X of again of recruiting our administered over ability or over may cancer the the cycles, that, beauty Phase the to a escaped is technology administered goal be system of in repeatedly of and to is durability be the week this The ensure said weekly cells XX of and will and immune it I immune which neoadjuvant have response to either sufficiently that surgery system II is in treat Study the chemotherapy. that active
results I'll effect. that that, mechanism talk an suggest having is about Initial this more.
safe be XX treatment surgery, ensure particularly follow-up of declared meter a XXX steady As for at mentioned had of the debulking patients. maximum part I GEN-X safe, protocol doses regarding that, is required of February, continued recommended news during beginning milligram the to the which stream per following a to call, and DSMB quarter. is encouraging dose In these the protocol we've interval per the the are
per two from the and next meter continue fully of evaluation dose squared, news-related Agency. approximately XXX profile a safety to II Phase recommendation expect in a positive will GEN-X at Orphan due to Final ovarian milligram to XXX per by another We DSMB the our be In of partly and Drug European Medicines therapy. weeks. milligrams meter status cancer March, was GEN-X the in granted very
quite an of data of it early both trials. efficacy not accomplishment, in sponsor just sources granted, our to as You it's a is a as supply some demonstration from incidents of may phase so drug know variety this requires well
things following in with exclusivity GEN-X the I designation procedure. It a authorization EMA’s It following the orphan authorization reduction approval. to value from provides this protocol all both FDA, providing member It a for to exclusivity other and also become very -- immediate allowing the GEN-X. of -- us very want very a eligible assistance. marketing that regulatory important designation EU. of gives The for of of positive note time received for from regulatory marketing access fees. approval, of the provides years is previously is It states XX market the all us would X-year This among of for manifold. centralized immediate
highly now In of with survival treated being tumor I know encouraging synthetic study In the OVATION-X. mid-March, Phase in in survival. patients an control Phase findings reported response may scores that portion to pulling OVATION-X, of scores, predictor Many highly a a versus our The progression us XX Company we surgical and reported I world encouraging synthetic from were of OVATION-X surgical that dependent statistically data prior dose improvement validated is overall management. comparing a leader patients arm. They're late-March, by provided PFS The clinical Medidata. arm name. free you is data OVATION-X control a
a cutting the that's to to is of which arm Medidata trial in by a or a approach of control for strategy. developed clinical all This The being edge is provide patients clinical trial. goal a replacement some
synthetic arm we our we XX almost we the patients, a our treated this when saw that doubling synthetic control hazard in patients of with ratio a the control doubling, a in sorry, time study to ratio I'm of the was arm. the GEN-X to median While compared when over while for X.XX progression hazard I Phase compare patients
As stand It's doesn't published it alone. experiences. said before, prior our clinical Phase remarkable, by data from I is impressive and with translational but I quite this supportive
we surprised other by translational weren't So, surprised clinical to action due the Phase I surprised our of we PFS or are outcomes largely data that experiences. magnitude. that weren't all the the and mechanism in from seeing We improved,
consideration that cancer with diagnosed strategies my strategies to a excited the and very ovarian in want cancer, hear strong the past. these development in believe we're we we’ve ovarian data. for advanced you and by them newly So, for with clinical and they I the accelerate program about discussed hope that GEN-X for voice FDA patients
data We of we encouraged a on on XX the point are based you the brief not outlining FDA results the these expecting response agency's our to have data view. to submitted this next XX the submitting brief a post and -- I'm and based in to I'm days. on
as be noted All for modest. worldwide I'd do need show call, to a is in development lucrative the a work. foundation the is efficacy in I modest delay point we're all, that in building believe an Well, continuous we suggested early plan there say asset GEN -X and what earlier work, to out, I should and being
program anticipate on assessing pointed or to would to I impact situation year weeks more than a over we end six as few the approximately did COVID in if that months. out due issue. Well, call X II past I we've decided months. by the evolving Study to our to During pointed out, X And Phase that significant not March, delay delays, X the not any our of GEN-X any, OVATION so, after the the portion amount
finished quality of the meets and product, our Company requirements. to due out a made assure largely quality our we This investigational by delay because me made specifications meets the ensure the an is of abundance decision by that to product of It's caution. product our our
COVID-XX-related that our with ThermoDox manufacturing true the strict in at facilities travel unable organizations, technical and to have their visitors this restrictions resources on our these contract limitations factories onsite we've formulation facility GEN-X, We as always as this during in But have mandated we present well by with product. be scientists the manufacturing our time. were for mandated some the runs to manufacturing always of that's manufacturing
that may to incumbent decided manufacturing our to I've delay be have product us postpone to make to treat until we September. investigational that, can we present, up upon It's sure patients. So, be available
next until out again II decided has few initiate abundance to not in have months. caution of we the of manufacturing So, resumed Phase
scheme, GEN-X a the success program. not in be said, this is success. just material the to this it's our of As for frankly, production overall and cautionary But are -- few months good I practice material would
it caused enormous an So, delay.
patient accelerate Meanwhile, we're looking for to ways enrollment.
So, study only have any months on impact may this a if few delay completion. minimal
the commence OVATION the early announced in So portion had second, XXXX. now quarter, that X guidance portion we second of previously Phase quarter, half the in is II will where commence the guidance will be to precise, that, of II the in Phase fourth the fourth our
elaborate of justified $XXX,XXX us the than return our for to want of made also what I loan to continues under and loan loan to SBA payroll The of release. yesterday. protection late after understanding very the application Act. as CARES was consultation to the become Congress that, was with our intent as in press to the program evolve believe and We administration with But of included our counsel, the us. on guidance consideration it and more the clear me clear consistent qualification some increasingly
from recent the some from not gotten but SEC. the guidance we've SBA only think I also
So rather to the Company provided fact funds, the the decision yesterday. uncertainty occurred U.S. after the by Treasury is deadline to that return the subject, Department than decided then
deferral negotiated taken $XXX,XXX our offset through documents than other to we've Mr. cash actions the than government. modest Horizon financial a renegotiated principal more that steps for adjustments My here to under offset, reductions, Now of offset we've payroll some and are example here, Loan more that Venture impact this compensate, once deferral flow. taking temporary payment has the and -- Church colleague may to returned to improve the signed we're the
achieve we everything Our quarter of many cash in have before do that, end ensure to runway that to that happens. that the I've the times commit the power ensure goal we our major -- I many as of through XXXX. we is quarter, repeated just will milestones expect always, And to second you
no have recent saying I've in company's orphan some for in resulted have day as show few significant time immediate regular designation fact been your stronger, from have drug quite we encouraging, which our agencies a GEN-X EMA. been issues as meetings regulatory each in various with points with conclude I'll now And and sound. So turns are what on fundamentals for here our been grow
strategy as be manufacturing solid. Our can characterized
pointed Our end redundancy focus as in during last has on pandemic this well, us served year out I discussion. our
cost enviable the the is promise no market with goods margins, costs, of product our Our of matter or the high gross region.
China life frankly, ThermoDox that's for in but HCC lifesaving gross to worldwide. margins, goods, provide potentially more know this ability Asia, importantly, where a the good us malady patients drug Southeast poor highly countries, to HCC, cost example concentrated You that addresses in of low saving assures
point I'll been have investigational standard Study products, investigational market As again. and cash management measure. of have our generating Jeff important two with of conclude will this blockbuster of point our Each focused products. cost by OPTIMA in the said and out, our transformational each potential it results. spending tight two The over or I've is potentially on and anyone's
patients, our forward have and product focus confidence will with we most that the looks every in reason our XXXX. to A medical of our Despite and year technologies, turmoil, our transformational community COVID-XX employees. balance for investigators Celsion collaborators, our investors. We have the to trials, our the and importantly, be believe every laser
Now call these to Jeff. the over I'd Jeff? turn like comments, to
